发明授权
US07935812B2 RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
有权
使用短干扰核酸（siNA）的RNA干扰介导的丙型肝炎病毒（HCV）表达的抑制
- 专利标题： RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
- 专利标题（中）： 使用短干扰核酸（siNA）的RNA干扰介导的丙型肝炎病毒（HCV）表达的抑制
-
申请号： US12418477申请日： 2009-04-03
-
公开(公告)号： US07935812B2公开(公告)日： 2011-05-03
- 发明人: James McSwiggen , David Morrissey , Roberto Guerciolini , Chandra Vargeese , Vasant Jadhav
- 申请人： James McSwiggen , David Morrissey , Roberto Guerciolini , Chandra Vargeese , Vasant Jadhav
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Laura M. Ginkel; David A. Muthard
- 主分类号： C07H21/04
- IPC分类号： C07H21/04 ; C07H21/02 ; A61K48/00
摘要：
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of hepatitis C virus (HCV) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in hepatitis C virus (HCV) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules capable of mediating or that mediate RNA interference (RNAi) against hepatitis C virus (HCV) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules.
公开/授权文献
信息查询
